Cart
sales@molnova.com
Sonepcizumab
CAS No. 1031360-18-5
Sonepcizumab( —— )
Catalog No. M36735 CAS No. 1031360-18-5
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P, with anti-cancer activity, useful for studying metastatic renal cell carcinoma (mRCC) and preventing eye scarring after glaucoma filtration surgery.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 629 | In Stock |
|
| 10MG | 847 | In Stock |
|
| 25MG | 1283 | In Stock |
|
| 50MG | 1693 | In Stock |
|
| 100MG | 2279 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSonepcizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P, with anti-cancer activity, useful for studying metastatic renal cell carcinoma (mRCC) and preventing eye scarring after glaucoma filtration surgery.
-
DescriptionSonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLPL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1031360-18-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pal SK, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer. 2017 Feb 15;123(4):576-582.?
molnova catalog
related products
-
(His(1-Me)2)-TRH
(His(1-Me)2)-TRH
-
Kankanoside O
Kankanoside O
-
CITCO
CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49?nM over pregnane X receptor (PXR), and no activity on other nuclear receptors.
